Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

190.43 +0.58 (+0.31%)
Streaming Delayed Price Updated: 11:33 AM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
21 22 Next >
News headline image
The Top 3 Healthcare Stocks to Buy in March 2024 ↗
There are still bargains to be had in the medical space. These are three top healthcare stocks to buy today. 
Via InvestorPlace
News headline image
Betting on Bitcoin: Does Coinbase Stock’s Surge Signal a Buy? ↗
vBitcoin has exploded higher over the past month setting an all-time record. That’s excellent news for Coinbase Global and COIN stock. 
Via InvestorPlace
News headline image
Thermo Fisher Stock Lights Up The Board, Soars 40% In 5 Months ↗
Thermo Fisher stock has risen more than 40% since October. Additionally, it's closed higher nine of the past 11 trading sessions. 
Via Investor's Business Daily
News headline image
Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Forecasting The Future: 4 Analyst Projections For Charles River ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 14, 2024 ↗
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion. 
Via Benzinga
News headline image
9 Analysts Have This to Say About Charles River ↗
 
Via Benzinga
News headline image
Expert Ratings for Charles River ↗
 
Via Benzinga
News headline image
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn’t Ignore. ↗
Looking for the next generational winner in healthcare stocks? These are three of the top prospects today. 
Via InvestorPlace
News headline image
Stocks Rebound As Investor Focus Shifts To Earnings, Bitcoin Tops $1 Trillion Value: What's Driving Markets Wednesday? ↗
The U.S. stock market attempted a rebound following Tuesday’s declines, which were sparked by a higher-than-expected inflation report in January, as investors refocused on corporate earnings. 
Via Benzinga
Topics Economy
News headline image
Charles River Laboratories Stock Surges On Upbeat Annual Outlook, But This Analyst Is Concerned ↗
Charles River Laboratories Q4 2023 revenue: $1.01 billion, down 7.9% YoY, beating consensus. Analysts note mixed Q4 performance, keeping Outperform rating. 
Via Benzinga
News headline image
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list... 
Via Benzinga
News headline image
Charles River Laboratories International Posts Upbeat Results, Joins Robinhood, Zillow, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Ten Big Losers To Start The Year. Tesla Isn't The Worst. ↗
Enphase Energy remains out of phase with the stock market. 
Via Investor's Business Daily
News headline image
Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Investing in the Aging Population: 3 Healthcare Stocks to Watch ↗
America is becoming a much older country on average. These three healthcare stocks are ideally positioned for this demographic shift. 
Via InvestorPlace
News headline image
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories to Present at Evercore ISI Investor Conference
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
The 3 Most Undervalued Tech Stocks to Buy Now: November 2023 ↗
Growth stocks are rallying but there are still bargains to be found. These three top tech picks can reward long-term investors. 
Via InvestorPlace
News headline image
Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Labs Q3 Revenue Jumps 4% Despite Softer Client Spending, Narrows Outlook ↗
Charles River Laboratories International Inc (NYSE: CRL) reported third-quarter (Q3) sales of $1.03 billion, an increase of 3.8% Y/Y, beating the  
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.